AMGEN AND SERVIER ANNOUNCE PRODUCT COLLABORATION

PRESS RELEASE

Under the terms of the agreement, Amgen has obtained commercial rights in the U.S. to Servier’s novel oral drug, approved in the EU as Coralan® (ivabradine), for chronic heart failure and stable angina in patients with elevated heart rates. Amgen has also received an exclusive option to develop and commercialize Servier’s investigational molecule, S38844, for cardiovascular diseases in the U.S. Currently, S38844 is in Phase 2 studies for the treatment of heart failure Through the collaboration, Servier has obtained rights to commercialize omecamtiv mecarbil in Europe. Omecamtiv mecarbil is an activator of cardiac myosin which is currently being tested for potential applications in the treatment of heart failure in patients with systolic dysfunction.

Silahkan klik di sini untuk informasi lebih detail.

Contact :

Amgen, Thousand Oaks
Ashleigh Koss, 805-313-6151 ( media )
Arvin Sood, 805-447-1060 ( investors )
-----------------------------------------------------------
Servier Communication Department
+30 (0)1 55 72 60 37